|Bid||15.25 x 900|
|Ask||15.65 x 800|
|Day's Range||15.26 - 15.78|
|52 Week Range||3.92 - 15.78|
|Beta (3Y Monthly)||2.40|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.25|
-- Updated Results from the Pomalyst® and Kyprolis® Arms of the Phase 1b/2 STOMP Study Evaluating Selinexor in Combination with Other Approved Myeloma Therapies in Relapsed or.
Karyopharm Therapeutics and Pieris Pharmaceuticals are climbing this week on positive news, while Supernus Pharmaceuticals takes a hit.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 4) Agile Therapeutics Inc (NASDAQ: AGRX )(follow-on rally ...
Cancer drug maker Karyopharm Therapeutics Inc on Monday reported revenues of $12.8 million for its third quarter, driven by the commercial launch of its recently approved cancer drug, Xpovio, exceeding analyst expectations. The drug, which treats relapsed or refractory multiple myeloma, was approved by the U.S. Food and Drug Administration on July 3, with shipments launched soon after. “Despite the fact that there are so many great drugs in multiple myeloma, many patients will progress through all those drugs," Michael Kauffman, chief executive officer of Karyopharm, said in a call with Reuters.
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 20.24% and 718.23%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
− XPOVIO Phase 2b STORM Study Results Published in The New England Journal of Medicine − − Achieved XPOVIO® U.S. Net Product Sales of $12.8 Million with Over 500 Prescriptions.
Biotech stocks extended their gains last week amid earnings news flow and the broader market strength. Large-cap pharma stocks saw particular strength. Here are the key catalytic event a biotech investor ...
Karyopharm Therapeutics Inc. (KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 169,500 shares of Karyopharm’s common stock to ten newly-hired employees, with a grant date of October 31, 2019. The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with NASDAQ Listing Rule 5635(c)(4). Each of the stock options has an exercise price of $11.70 per share, the closing price of Karyopharm’s common stock on October 31, 2019.
Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to […]
HENDERSONVILLE, TN / ACCESSWIRE / October 30, 2019 / The Law Offices of Timothy L. Miles, who has been leading the fight to protect shareholder rights for over 18 years, reminds investors that a purchaser ...
NEWTON, Mass., Oct. 28, 2019 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that it will report third quarter 2019.
Shareholder rights law firm Robbins Arroyo LLP reminds investors that a purchaser of Karyopharm Therapeutics Inc. (KPTI) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between March 2, 2017 and February 22, 2019, and the Securities Exchange Act of 1933 for conduct related to the company's public offerings on April 28, 2017 and May 7, 2018. Karyopharm is a clinical-stage pharmaceutical company focused on the development of drugs for the treatment of cancer. If you suffered a loss as a result of Karyopharm's misconduct, click here.
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shareholders should be happy to see the share price up 21% in the last...
Bragar Eagel & Squire is investigating certain officers and directors of Healthcare Services Group, In. Bragar Eagel & Squire is investigating certain officers and directors of Healthcare Services Group, Inc. following a class action complaint that was filed against Healthcare Services on March 22, 2019.
NEW YORK, NY / ACCESSWIRE / September 23, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine ...
NEW YORK, NY / ACCESSWIRE / September 23, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Karyopharm Therapeutics Inc. ("Karyopharm" or "the Company") (NASDAQ:KPTI) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Karyopharm securities between March 2, 2017 and February 22, 2019, both dates inclusive. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. The lawsuit alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that material adverse information.
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided.
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Karyopharm Therapeutics Inc. (“Karyopharm” or “the Company”) (NASDAQ: KPTI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Karyopharm repeatedly hyped the commercial prospects of its drug selinexor.
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with losses in excess of $100,000 that they have only until September 23, 2019 to file lead plaintiff applications in a securities class action lawsuit against Karyopharm Therapeutics Inc. (KPTI). Investor losses must relate to purchases of the Company’s shares between March 2, 2017 and February 22, 2019 or issued in connection with its April 2017 or May 2018 public offering. This action is pending in the United States District Court for the District of Massachusetts. If you purchased shares of Karyopharm and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (email@example.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-kpti/ to learn more.